In this report. we present a case of nonsmall-cell lung cancer with anaphylaxis after 41 courses of pembrolizumab along with adrenal insufficiency as an immune-related adverse event (irAE). A 73-year-old man with no allergic disease started pembrolizumab for postoperative recurrence of lung cancer. After four courses. https://www.markbroyard.com/mega-price-south-carolina-gamecocks-usc-gamecocks-online-great-buy/